COMP <GO>
XTNT vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
Xtant Medical Holdings Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: XTNT 4
— ABBV 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $0.29 (+1.54%) • MKT CAP: $40.7M
roic
12.80%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XTNT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XTNT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.90% | 70.20% | -7.30 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 12.80% | 29.00% | -16.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.7x | 33.3x | -29.60 | XTNT | /valuation <GO> |
| Free Cash Flow Yield | 24.95% | 3.47% | +21.48 | XTNT | /fcf-yield <GO> |
| Operating Margin | 5.40% | 24.60% | -19.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 6.90% | -6.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 14.20% | 8.60% | +5.60 | XTNT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.33 | -5.13 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | XTNT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.9 | 65.1 | -30.16 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $40.7M | $513.86B | -$513.82B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XTNT REV | ABBV REV | XTNT GROSS % | ABBV GROSS % | XTNT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $133.9M | $61.16B | 62.9% | 70.2% | $10.2M | $17.82B |
| FY 2024 | $117.3M | $56.33B | 58.2% | 70.0% | -$16.0M | $17.83B |
| FY 2023 | $91.3M | $54.32B | — | — | -$9.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XTNT // BETA —
ABBV // BETA 1.15